Neo Medical Secures $68 Million to Drive Innovation in Spine Surgery

Swiss-based Neo Medical has secured a $68 million equity investment in a landmark Series B financing round, led by Gyrus Capital, to accelerate global growth. The funding, including converted shareholder loans, positions Neo to expand its reach, particularly in the U.S., and enhance its portfolio of spine surgery technologies, with a focus on its AI-driven intraoperative data platform, ADVISE™, and the innovative Neo Universal™ system. These technologies aim to disrupt the $7.6 billion global thoracolumbar fusion market by improving patient outcomes and operational efficiencies.

Neo Medical CEO and Co-Founder, Vincent Lefauconnier, emphasized the urgent need for innovation in the spine surgery market, which has seen little change in decades. With Neo Universal™, the company introduces groundbreaking approaches that add value both inside and outside the operating room. This new funding will help the company scale its operations, reach more healthcare providers, and improve patient care through its advanced surgical technologies.

Since its commercial launch in 2016, Neo Medical’s technologies have treated 36,000 patients, reducing implant failure rates by up to three times and surgery time by nearly 30%. The company’s rapid growth and proven outcomes make it a strong contender to revolutionize spine surgery in both inpatient and outpatient settings, with future plans to extend its platform for complex surgeries.